THERAMEX
12.7.2021 14:38:06 CEST | Business Wire | Press release
Theramex, a CVC Capital Partners ("CVC") portfolio company focused on Women’s Health has announced that Sigurd (Sig) Kirk has been appointed as a member of the Board of Directors for Theramex. Theramex is a leading global speciality pharmaceutical company dedicated to women and their health.
Based in the United States, Sig is a senior business development executive with 15+ years of pharmaceutical experience gained in global multi-billion dollar publicly traded companies. His strategic leadership, experience in high value merger and acquisition transactions, and deep financial skills, have driven exceptional growth in the businesses he has supported. In his most recent position, Sig was Executive Vice President, Corporate Business Development at Allergan plc. He started his career at Deloitte & Touche as an Audit Manager earning his CPA certification and received his Bachelor of Business Administration degree from Pace University.
Theramex Chairman, Fred Hassan said, "Sig joins us at a time when Theramex is going from strength-to-strength. He is a talented global leader with exceptional acquisition and business development experience. I look forward working with him to further establish Theramex as the leading global platform for women's health products."
Commenting on his appointment, Sig Kirk said, “It’s a privilege to join the Theramex board and I look forward to meaningful contribution to the board and management team as Theramex charts out the next chapter of growth in Women’s Health ”.
About Theramex
With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, Theramex supports women at every stage of their lives. Its commitment is to listen and understand women, to serve their needs, and to offer innovative and effective healthcare solutions which will improve their lives.
Date of Preparation: 09/07/2021
THX_HQ_PRESSR_004755
View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005463/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 13:30:00 CET | Press release
The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship between target engagement and clinical improvement in psoriasis and atopic dermatitis RLS-1496 is a first-in-class disease-modifying mechanism targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases of aging A second study for RLS-1496 – a Phase 1b/2a study in actinic keratosis (precancerous skin lesions) – is underway in the United States, with completion expected later this year Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, to moderate panel on senescence and skin at the Dermatology Innovation Forum (DIF) during the American Academy of Dermatology (AAD) annual meeting on Thursday, March 26, at 1:05 pm MT in Denver Oral presentation of data accepted at the Society for Investigative Dermatology (SID) from May 13-16, 2026, in Chicago Rubedo L
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 13:30:00 CET | Press release
COMPASS is one of the largest public‑private partnerships under the European Union’s (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by
M1X Global Announces Public Launch and Oversubscribed $3 Million Angel Round to Scale On-Chain Sovereign Finance26.3.2026 13:13:00 CET | Press release
M1X Global, a sovereign financial infrastructure and technology company, today announced its public launch alongside the close of an oversubscribed $3 million angel round. The funding, spanning strategic investments and grants, will support platform development and accelerate regulated institutional adoption of USDM1, the first USD-denominated, treasury collateralized sovereign debt instrument issued natively by a sovereign on public blockchain infrastructure. The $3 million in funding drew participation from leading figures across global capital markets and digital asset infrastructure, including Balaji Srinivasan, former CTO of Coinbase; Tama Churchouse, CEO of Cumberland Labs; Richard Gorelick, former Head of Market Structure at DRW; and Dan Robichaud, former CIO at Intel. Institutional participation from FJ Labs and grant funding from Stellar Development Foundation reflect strong alignment between private capital and mission-driven partners advancing blockchain-based market develop
500 Global Taps Former IFC CIO As Firm Expands Global Investment Platform26.3.2026 13:00:00 CET | Press release
Atul Mehta brings three decades of global investment leadership to board as 500 Global scales platforms aligning venture capital with national innovation and economic growth agendas. 500 Global today announced the appointment of Atul Mehta to its Board of Directors, marking an important step in the firm’s continued evolution as a global venture platform and institutional asset manager. Mehta brings more than three decades of global investment and institutional leadership experience at a time when 500 Global has observed governments, multilateral institutions, and long-term capital providers rethinking how technology-led growth is financed and scaled. He has held senior roles across private capital and development finance, including at the International Finance Corporation (IFC), where he managed multi-billion-dollar portfolios spanning technology, venture funds, infrastructure, agribusiness, healthcare, education, and financial services across emerging markets. Over his career, he has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom